Literature DB >> 1293050

Transintestinal elimination of ciprofloxacin in humans--concomitant assessment of its metabolites in serum, ileum and colon.

B Viell1, B Krause, K H Vestweber, S Schaaf, H Scholl.   

Abstract

Ciprofloxacin (200 mg) was infused to seven patients at the beginning of elective colorectal surgery. Thirty minutes after the end of infusion (i.e. 60 min after the start of the operation) ciprofloxacin reached concentrations of 1.60 mg/l in serum and of 3.42-6.07 mg/kg fresh weight in the ileum and colon. During the next 30 min (90 min after the start of operation) the concentration of ciprofloxacin in serum decreased to 86% of its initial level, but this decrease was less rapid than that observed in the ileal (to 56.8%) or colonic (to 74.8%) mucosa. Three metabolites could be identified (desethylen-, sulpho-, oxociprofloxacin). Initially, at 60 min the amount of these metabolites was about 15% of the total drug concentration in serum, but only 2-3% of that in the gut tissues. At 90 min the relative amount of metabolites was increased in serum as well as in the gut tissues. It is concluded that transintestinal elimination of ciprofloxacin is a general feature of the whole gut. Obviously, the elimination process is not due to degradation of ciprofloxacin within the gut wall.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1293050     DOI: 10.1007/bf01710676

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

Review 1.  [Perioperative use of antibiotics for preventive indications].

Authors:  K H Vestweber; A Becker; B Viell
Journal:  Klin Wochenschr       Date:  1991

2.  Tissue penetration and metabolism of ciprofloxacin.

Authors:  R Wise; I A Donovan
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

Review 3.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

4.  Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.

Authors:  H M Siefert; D Maruhn; W Maul; D Förster; W Ritter
Journal:  Arzneimittelforschung       Date:  1986-10

5.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

Review 6.  Pharmacokinetics of ciprofloxacin.

Authors:  T Bergan; A Dalhoff; R Rohwedder
Journal:  Infection       Date:  1988       Impact factor: 3.553

7.  The pharmacokinetics of ciprofloxacin in patients with impaired renal function.

Authors:  J Boelaert; Y Valcke; M Schurgers; R Daneels; M Rosseneu; M T Rosseel; M G Bogaert
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

8.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  [Ciprofloxacine: evaluation of its biliary elimination in man].

Authors:  J M Brogard; F Jehl; J P Arnaud; P Lévy; F Peladan; J F Blicklé; H Monteil
Journal:  Schweiz Med Wochenschr       Date:  1985-03-30

10.  Overview of preclinical studies with ciprofloxacin.

Authors:  C C Sanders; W E Sanders; R V Goering
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

View more
  2 in total

1.  Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

Authors:  W A Krueger; G Ruckdeschel; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.